Eprotirome (KB2115), a synthetic thyroid hormone mimetic, is a thyroid hormone receptor agonist.

在适度超重及高胆固醇血症患者中，Eprotirome (KB2115) 被发现安全且易于耐受，并在14天治疗后使总胆固醇和LDL胆固醇降低了高达40%。胆酸合成被激活，而未发现胆固醇产量增加[1]。经KB2115处理的小鼠展示了空腹血糖增加，尽管KB2115并未提高空腹胰岛素水平[2]。

A catheter was implanted into the right internal jugular vein before the hyperinsulinemic-euglycemic clamp. After recovery, mice were administered GC-1 (0.03 or 0.3 mg/kg), KB2115 (0.3 mg/kg) or T3 (0.06 mg/kg) via intraperitoneal injection for 10 days. On the day of the clamp experiment, conscious, overnight-fasted mice received a primed (10 μCi) and constant rate intravenous infusion (0.1 uCi/min) of [3-3H] glucose to measure basal glucose turnover. After 60–75 minutes of labeled glucose infusion, the hyperinsulinemic-euglycemic clamp was performed with continuous infusion of insulin (12 mU/kg/min) and variable infusion of 25% glucose to maintain euglycemia (~120 mg/dl). Blood samples were collected by tail bleeding (approximately every 10 min) to measure blood glucose concentrations [2].